CVS Health Corporation $CVS Shares Sold by Fort Washington Investment Advisors Inc. OH

Key Points

• Fort Washington Investment Advisors Inc. OH reduced its CVS Health stake by 5.7% in the third quarter, selling 40,931 shares and retaining 681,086 shares worth approximately $58.4 million. Institutional investors collectively own 80.66% of CVS.
• CVS reported quarterly earnings of $2.58 per share, exceeding estimates of $1.87, while revenue rose 7.3% year over year to $106.1 billion. The company also declared a quarterly dividend of $0.665, equivalent to a 2.9% annualized yield.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $107.80 versus the reported share price of $90.42. However, CVS agreed to pay $315 million to resolve allegations involving unlawful opioid prescriptions, creating financial, reputational and compliance risks.

Fort Washington Investment Advisors Inc. OH trimmed its holdings in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 5.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 681,086 shares of the pharmacy operator's stock after selling 40,931 shares during the quarter. Fort Washington Investment Advisors Inc. OH owned about 0.05% of CVS Health worth $58,362,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Mather Group LLC. grew its holdings in shares of CVS Health by 41.2% during the third quarter. Mather Group LLC. now owns 14,807 shares of the pharmacy operator's stock worth $1,269,000 after purchasing an additional 4,319 shares in the last quarter. Cliftonlarsonallen Wealth Advisors LLC increased its position in shares of CVS Health by 9.5% in the third quarter. Cliftonlarsonallen Wealth Advisors LLC now owns 12,130 shares of the pharmacy operator's stock worth $1,039,000 after purchasing an additional 1,053 shares during the last quarter. Fortitude Family Office LLC increased its position in shares of CVS Health by 110.6% in the third quarter. Fortitude Family Office LLC now owns 990 shares of the pharmacy operator's stock worth $85,000 after purchasing an additional 520 shares during the last quarter. Western Financial Corp CA purchased a new stake in CVS Health in the third quarter valued at approximately $4,509,000. Finally, Sanders Morris Harris LLC purchased a new stake in CVS Health in the third quarter valued at approximately $576,000. 80.66% of the stock is currently owned by institutional investors.

CVS Health Stock Up 3.3%

Shares of CVS opened at $90.42 on Thursday. CVS Health Corporation has a 1 year low of $69.51 and a 1 year high of $110.68. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. The stock has a 50 day simple moving average of $91.88 and a two-hundred day simple moving average of $92.87. The firm has a market cap of $115.64 billion, a P/E ratio of 23.92, a P/E/G ratio of 0.82 and a beta of 0.60.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, topping the consensus estimate of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The firm had revenue of $106.10 billion for the quarter, compared to the consensus estimate of $100.03 billion. During the same period last year, the firm posted $1.81 earnings per share. The business's revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, analysts forecast that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Thursday, October 22nd will be paid a $0.6650 dividend. The ex-dividend date of this dividend is Thursday, October 22nd. This represents a $2.66 annualized dividend and a yield of 2.9%. CVS Health's payout ratio is currently 70.37%.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Aetna reported that more than 69% of its Medicare Advantage members are enrolled in plans rated four stars or higher for 2027, marking the third consecutive year of strong performance among large publicly traded insurers. Higher star ratings can support member retention and Medicare Advantage revenue. Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience
• Positive Sentiment: MinuteClinic received its seventh consecutive Joint Commission accreditation, with approximately 80% of surveyed locations offering primary care. The recognition supports CVS’s strategy to expand accessible, lower-cost healthcare services. MinuteClinic accreditation
• Positive Sentiment: CVS opened its first pharmacy-focused location in the Boston area, aimed at improving access to medications, vaccinations and other pharmacy services in underserved communities. CVS Pharmacy opens Boston-area location
• Neutral Sentiment: One analyst comparison said CVS currently benefits from stronger returns, rising earnings estimates and a lower valuation than Alignment Healthcare, with Aetna’s turnaround supporting the investment case. This is analyst sentiment rather than a new company financial result. CVS versus Alignment Healthcare
• Negative Sentiment: CVS Pharmacy and related entities agreed to pay $315 million to resolve a U.S. Justice Department case alleging that pharmacies filled unlawful or medically unnecessary opioid and other controlled-substance prescriptions from 2013 through 2025 and submitted false claims to federal healthcare programs. CVS admitted no wrongdoing and strongly disputes the allegations, but the settlement creates a direct cost, reputational damage and additional compliance obligations, including tighter prescription monitoring. The development is the main reason the stock is likely under pressure, while also renewing scrutiny of former and current company leadership. Justice Department CVS opioid settlement

Wall Street Analysts Forecast Growth

CVS has been the subject of a number of research reports. Bank of America boosted their price target on shares of CVS Health from $100.00 to $110.00 and gave the stock a "buy" rating in a research note on Monday, June 22nd. Piper Sandler set a $112.00 price objective on shares of CVS Health in a research report on Wednesday, September 9th. UBS Group restated a "buy" rating on shares of CVS Health in a research report on Tuesday, September 22nd. Wall Street Zen raised shares of CVS Health from a "buy" rating to a "strong-buy" rating in a report on Sunday. Finally, Cantor Fitzgerald reiterated a "neutral" rating on shares of CVS Health in a research report on Friday, October 9th. Twenty equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $107.80.

CVS Health Profile

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company's major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.